Filing Details

Accession Number:
0001144204-15-040971
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-07-02 21:54:07
Reporting Period:
2015-06-30
Filing Date:
2015-07-02
Accepted Time:
2015-07-02 21:54:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1072379 Northwest Biotherapeutics Inc NWBO Pharmaceutical Preparations (2834) 943306718
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1626920 Cognate Bioservices, Inc. 7513 Connelley Drive
Hanover MD 21076
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.001 Disposition 2015-06-30 650,000 $4.00 19,578,482 No 4 S Direct
Common Stock, Par Value $0.001 Disposition 2015-06-30 1,118,092 $4.22 18,460,390 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. Cognate entered into a $3 million convertible debt financing with an unrelated third party investor, secured by Cognate assets. The debt was convertible, at the investors' election, into common shares of Northwest Biotherapeutics restricted stock owned by Cognate. The third party investors elected to convert the debt and receive repayment in Common Shares rather than in cash. Therefore, on June 30, 2015, Cognate transferred 650,000 restricted common shares of Northwest Biotherapeutics, Inc.to this third party to settle the debt..
  2. Does not include 10,432,387 shares of common stock underlying currently exercisable warrants.
  3. Cognate entered into two convertible loans, each in the amount of $2,500,000, to an unrelated third party investor in June and July, 2014, and provided the proceeds of the financings for Northwest Biotherapeutics programs. The debt was secured by shares of Northwest Biotherapeutics owned by Cognate and was convertible, at the investors' election, into Northwest Biotherapeutics, Inc. common shares owned by Cognate at a fixed conversion price. The third party investors elected to take repayment in Common Shares rather than in cash. Therefore, on June 30, 2015, Cognate transferred 1,118,092 Common Shares to settle the debt notes..